Acute renal failure

  title={Acute renal failure},
  author={Norbert H. Lameire and Wim van Biesen and Raymond C Vanholder},
  journal={The Lancet},

Figures and Tables from this paper

Novel Aspects of Pharmacological Therapies for Acute Renal Failure
New biomarkers, including neutrophil gelatinase-associated lipocalin (NGAL), liver-type fatty acid binding protein (L-FABP) or kidney injury molecule-1 (KIM-1) that increase prior to the serum creatinine elevation are promising and have been proven to be useful in this regard in a few clinical trials.
[Acute or rapidly progressive renal failure in elderly patients].
The differential diagnosis of a rapid decline includes crescentic glomerulonephritis and acute interstitial nephritis, which has to be distinguished from prerenal or postrenal causes.
Pathophysiology of ischaemic acute kidney injury
The concept of ‘organ cross-talk’ will be introduced as a potential explanation for the higher mortality observed with acute kidney injury that might be deemed modest in conventional biochemical terms.
Behavior of acute renal failure in children presenting with severe sepsis
The non-appropriate diuretic response to fluid-therapy, the hemodynamic instability during more the 24 hours, the myocardial dysfunction and the use of nephrotoxin drugs increased the ARF risk in cases of severe sepsis, which to double the mortality in relation to patients maintaining their renal function.
What Clinical and Laboratory Parameters Distinguish Between Acute and Chronic Renal Failure
It is concluded that the duration of symptoms, quantity of urine, blood pressure, and serum urea levels are distinguishing parameters between ARF and CRF, while serum creatinine and PCV are not.
Epidemiology and prognosis of critically ill patients with acute renal failure
The fact that ARF conveys a significant risk of death and that hospital outcome of patients treated with renal replacement therapy seems to improve in the last decade is highlighted.
Pathophysiological mechanisms and drugs leading to decrease in renal function in congestive heart failure
Drawing conclusions of large trials have not proved fully applicable but should be made so by means of trials including a representative number of patients suffering from both cardiac and renal failure, as far more of them can be found in "real-life" conditions (epidemiologically).
Urinary biochemistry in experimental septic acute renal failure.
The findings suggest that, in sepsis, these urinary biochemical changes are not reliable markers of renal hypoperfusion.
Renal replacement therapy in acute kidney injury: intermittent versus continuous? How much is enough?
Several unanswered questions, such as the timing of initiation and cessation of RRT, the modification of dialysis parameters over the course of acute kidney injury and the influence of fluid status need to be addressed in future trials in order to improve outcomes related to this condition.


Acute renal failure: definitions, diagnosis, pathogenesis, and therapy.
The epidemiology and pathophysiology of ARF are discussed, including the vascular, tubular, and inflammatory perturbations and implications for potential future therapies to decrease the high mortality.
Prevention and nondialytic treatment of acute renal failure
Although the results are still conflicting, the majority indicates that acetylcysteine, when applied together with adequate volume expansion, may be a useful drug to incorporate in the standard treatment procedures in patients at risk for acute renal failure.
What can be done about acute renal failure?
  • J. Kellum
  • Medicine, Biology
    Minerva anestesiologica
  • 2004
Data suggest that NAC can reduce the incidence of ARF secondary to radio-contrast agents and improved techniques for RRT and, perhaps, new drugs aimed at improving cellular repair, will improve outcome from ARF in the future.
Interventions in clinical acute renal failure: what are the data?
  • J. Conger
  • Medicine
    American journal of kidney diseases : the official journal of the National Kidney Foundation
  • 1995
Pharmacologic treatment of acute renal failure in sepsis
Activated protein C and steroid replacement therapy have been shown to reduce mortality in patients with sepsis and are now accepted adjunctive treatment options for sepsi in general.
Pathophysiology of ischaemic acute renal failure.
Acute toxic renal failure.
  • P. Evenepoel
  • Medicine, Biology
    Best practice & research. Clinical anaesthesiology
  • 2004
Acute renal failure due to nephrotoxins.
A persistent homogeneous reduction in renal cortical perfusion sufficient to induce the cessation of glomerular filtration and thus account for the failure of renal function is suggested.
Animal models of acute tubular necrosis
Advanced techniques are critically needed to establish noninvasively the dynamic status of renal parenchymal microcirculation and the distribution of intrarenal oxygenation and to identify evolving cellular energy depletion and tubular cell damage.
Recent advances in the pathophysiology of ischemic acute renal failure.
As covered in the preceding sections, acute renal failure (ARF) is a syndrome associated with high mortality in humans. Current therapy is limited to supportive measures and preventive strategies,